Drugs / ThINKK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07518654 | May 2026 → May 2029 expected | acute lymphoblastic leukemia, acute myeloid leukemia, neuroblastoma | Michel Duval | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ThINKK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07518654 ↗ |
| Known as | Therapeutic Inducers of Natural Killer Killing | “Therapeutic Inducers of Natural Killer Killing (ThINKK)” NCT07518654 ↗ |
| Modality | Cell therapy | “A first-in-class adoptive immunotherapy we called ThINKK” NCT07518654 ↗ |